Daijiworld Media Network - New Delhi
New Delhi, Nov 13: The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed strict monitoring of the implementation of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer medicines, with revised prices coming into effect from November 9.
According to an official statement issued on Friday, the latest revised price lists, based on submissions received from pharmaceutical companies up to November 11, 2026, have been made available on the NPPA website and the Pharma Sahi Daam app and portal.
All manufacturers, retailers, dealers, stockists, hospitals and medical institutions have been directed to comply with the revised prices and prominently display the updated price lists at their premises and on their websites.
State Drug Controllers (SDCs) have also been instructed to closely monitor compliance among manufacturers, dealers, hospitals and medical institutions to ensure that patients receive the full benefit of the reduced maximum retail prices (MRPs).
Any violation may invite overcharging proceedings under the provisions of the Drugs (Prices Control) Order (DPCO), 2013, the statement said.
Patients and members of the public can report complaints relating to overcharging, shortages or non-availability of medicines through the Pharma Sahi Daam app or portal, the NPPA helpline or email.
The State Drug Controllers have been asked to submit their Action Taken Reports to the NPPA by November 16, 2026.
The Centre has introduced a 30 per cent cap on trade margins for 137 non-scheduled anti-cancer medicines to reduce the financial burden on patients undergoing cancer treatment.
Through an order issued on October 17, the NPPA brought these medicines under the TMR mechanism, restricting trade margins across the supply chain to 30 per cent.
By November 9, a total of 85 pharmaceutical companies had submitted revised MRPs for 121 of the 137 medicines, covering 1,366 stock-keeping units (SKUs).
The highest reported price reduction stood at 96.45 per cent, while more than 650 formulations recorded MRP reductions exceeding 50 per cent. The largest number of price reductions fell within the 50 to 75 per cent range.
The estimated savings for patients are pegged at Rs 3,541 crore. According to the official statement, the savings were calculated by comparing the original and revised prices and applying the difference to sales volumes recorded between April 2025 and March 2026.
The 30 per cent trade margin cap applies across the pharmaceutical supply chain, including retail and hospital pharmacies. It covers the listed medicines irrespective of their dosage or form, including tablets and injections, as well as medicines sold individually or in combination formulations.